ABX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ABX is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The chart is bullish, but the stock is already overbought and options/analyst signals are mixed. Because the user is unwilling to wait for a better entry, I would still not call this a buy today; the better call is hold and wait for a calmer entry or clearer fundamental confirmation.
The short-term trend is bullish: MACD histogram is positive and expanding, and the moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200. Price at 11.86 is above the first resistance (R1 11.465) and approaching R2 12.121, which shows momentum. However, RSI_6 is 87.3, which is deeply overbought and suggests the current move is extended. Net technical read: bullish trend, but the current price is stretched and not an ideal fresh entry for a long-term beginner.
Recent news is constructive: the court allowed Abacus's lawsuit against Coventry to proceed, which supports Abacus's claims and could improve the company’s position in an ongoing competitive dispute. Hedge funds are also buying aggressively, with buying amount up 182.18% over the last quarter. Analyst sentiment has improved somewhat, with Freedom Broker initiating Buy coverage at $13 and Piper Sandler raising its target to $10 after a core beat and higher 2026 guidance. The company also raised its 2026 adjusted net income guidance midpoint to $103M from $100M.
The stock is technically overbought after a sharp run. Piper Sandler still rates the stock Neutral, and its latest price target of $10 is below the current price of 11.86, which signals limited near-term upside from a conservative Wall Street view. The latest financial snapshot was unavailable, so there is no clean quarter-by-quarter confirmation of accelerating fundamentals. Insiders are neutral, and there is no recent congress trading data to reinforce conviction. The stock trend model also suggests only modest near-term gains and a possible small pullback next day.
Financial data was not fully available, but the latest quarter appears to have been strong enough for management to raise 2026 guidance. Piper Sandler noted Abacus posted a core beat versus its estimates, though slightly below the Street, and the company raised its 2026 adjusted net income guidance midpoint to $103M from $100M. That suggests improving earnings momentum, but without the full quarter revenue and margin details, the latest financial picture remains incomplete.
Analyst sentiment is mixed but slightly improving. Piper Sandler raised its target to $10 from $9.50 and kept a Neutral rating, while Freedom Broker initiated with a Buy and $13 target. Earlier Piper Sandler had cut its target to $9.50 from $11 due to sector and macro headwinds. Wall Street pros: improving guidance, core beat, and a favorable long-term industry backdrop for policy monetization. Wall Street cons: one major house still Neutral, target levels remain close to or below the current price, and the stock appears to have already priced in a lot of the good news.
